Curative effect of stereotactic body radiotherapy for unresectable massive primary liver cancer

Dang,Ya‑Zheng; Li,Xin; Huang,Shi‑Gao; Lu,Wan‑Ling; Wang,Guodong; Zhang,Dongxian; Wang,Qian‑Yun

doi:10.3892/mco.2017.1255

Curative effect of stereotactic body radiotherapy for unresectable massive primary liver cancer

Authors:
- Ya‑Zheng Dang
- Xin Li
- Shi‑Gao Huang
- Wan‑Ling Lu
- Guodong Wang
- Dongxian Zhang
- Qian‑Yun Wang
View Affiliations

Affiliations: Department of Radiation Oncology, 323 Hospital of People's Liberation Army, Xi'an, Shaanxi 710054, P.R. China
Published online on: May 9, 2017 https://doi.org/10.3892/mco.2017.1255
Pages: 911-916

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to evaluate the curative effect of gamma knife stereotactic body radiotherapy (SBRT) for unresectable massive primary liver cancer. A total of 69 patients with unresectable massive (>10 cm) primary liver cancer who were treated by SBRT at the Department of Radiation Oncology of the 323 Hospital of People's Liberation Army (Xi'an, China) between October, 2006 and October, 2010, were analyzed. According to the Union for International Cancer Control TNM staging guidelines, the patients were graded as stage T1 (n=8), T2 (n=12), T3 (n=21) and T4 (n=28). None of the patients had lymph node metastasis, whereas 45 patients had portal vein tumor thrombosis. The Child‑Pugh class was A (n=49), B (n=15) and C (n=5). The visible tumor volume ± standard deviation was 810±213 cm3. The patients received a total radiation dose of 50‑60 Gy, with a dose fractionation of 4‑6 Gy/fx, administered for a total of 9‑12 times, 2‑5 times/week. A total of 8 patients succumbed to the disease within 3 months after gamma knife treatment and were not included in the evaluation of the curative effect. The total effectiveness rate was 59.0% (36/61) and the median survival was 17.4 months for all the patients included in the study. The 1‑, 2‑, and 3‑year overall survival rates were 71, 30 and 22%, respectively. In conclusion, SBRT appears to be effective for unresectable massive primary liver cancer.

View Figures

View References

1	Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K and Takashima S: Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology. 148:397–401. 1983. View Article : Google Scholar : PubMed/NCBI
2	Arata S, Tanaka K, Okazaki H, Kondo M, Morimoto M, Saito S, Numata K, Nakamura S and Sekihara H: Risk factors for recurrence of large HCC in patients treated by combined TAE and PEI. Hepatogastroenterology. 48:480–485. 2001.PubMed/NCBI
3	A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. N Engl J Med. 332:1256–1261. 1995. View Article : Google Scholar : PubMed/NCBI
4	WHO, . Handbook for reporting the results of cancer treatment. Offset Publication No. 48. World Health Organization; Geneva: pp. 34–35. 1979
5	Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Onco. 12:649–655. 198:
6	Cancer Therapy Evaluation Program. http://ctep.cancer.gov/reporting/ctc.htmlFebruary 25–2010
7	Cox JD, Stetz J and Pajak TF: Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys. 31:1341–1346. 1995. View Article : Google Scholar : PubMed/NCBI
8	Pavy JJ, Denekamp J, Letschert J, Littbrand B, Mornex F, Bernier J, Gonzales-Gonzales D, Horiot JC, Bolla M and Bartelink H: EORTC Late Effects Working Group. Late effects toxicity scoring: The SOMA scale. Int J Radiat Oncol Biol Phys. 31:1043–1047. 1995. View Article : Google Scholar : PubMed/NCBI
9	Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD and Fajardo LF: Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys. 31:1237–1248. 1995. View Article : Google Scholar : PubMed/NCBI
10	Shetty K, Rybicki L and Carey WD: The Child-Pugh classification as a prognostic indicator for survival in primary sclerosing cholangitis. Hepatology. 5:1049–1053. 1997. View Article : Google Scholar
11	Glouse ME, Stokes KR, Kruskal JB, Perry LJ, Stuart KE and Nasser IA: Chemoembolization for hepatocellular carcinoma: Epinephrine followed by a doxorubicin-ethiodized oil emulsion and gelatin sponge powder. J Vasc Interv Radiol. 4:717–725. 1993. View Article : Google Scholar : PubMed/NCBI
12	Nakai M, Sato M, Kawai N, Minamiguchi H, Masuda M, Tanihata H, Takeuchi T, Terada M and Kishi K: Hepatocellular carcinoma: Involvement of the internal mammary artery. Radiology. 219:147–152. 2001. View Article : Google Scholar : PubMed/NCBI
13	Seong J, Park HC, Han KH, Lee DY, Lee JT, Chon CY, Moon YM and Suh CO: Local radiotherapy for unresectable hepatocellular carcinom a patients who failed with transcatheter arterial chemoembolization. Int J Radia Oncol Biol Phys. 47:1331–1335. 2000. View Article : Google Scholar
14	Xiong LS, Dong ZX, Liang JG, Long C and Li YY: Three-dimensional conformal radiotherapy(3-DCRT) for 69 cases of massive primary liver cancer. Chin Oncol. 16:478–479. 2006.
15	Dang YZ, Huang SG, Lu WL, Wu FW and Wang QY: Curative effect of stereotactic body radiotherapy on hepatic hilar carcinoma. Mol Clin Oncol. 2:1135–1138. 2014.PubMed/NCBI
16	Park C, Papiez L, Zhang S, Story M and Timmerman RD: Universal survival curve and single fraction equivalent dose: Useful tool in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys. 70:847–852. 2008. View Article : Google Scholar : PubMed/NCBI
17	Fletcher GH: Clinical dose-response curve of subclinical aggregates of epithelial cells. J Radiol Electrol Med Nucl. 53:201–206. 1972.PubMed/NCBI